Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/15 | $35,000,000 | Series A |
Amgen Business Development Atlas Venture Elliott Sigal Novartis Institute for Biomedical Research | undisclosed |
